StreetAlpha.app
Home › Stocks › DNTH

Dianthus Therapeutics, Inc. (DNTH)

Healthcare
$86.98
▼ −2.87%
LAST CLOSE · NOV 17

Dianthus Therapeutics develops experimental drugs for severe autoimmune diseases, led by the antibody claseprubart. It last closed at $86.98 on Nov 17, down 2.87% on the day. The average 12-month price target from 3 analysts is $134.67 (+54.8% from the last close), with a high of $156.00 and a low of $113.00. Analyst consensus is Strong Buy, based on the latest ratings from 3 firms (3 buy, 0 hold, 0 sell). Over the past 90 days StreetAlpha recorded 1 whale options trade in DNTH, 0% of them bullish and 100% bearish. In the past 30 days there were 3 dark pool prints totaling $5.1M, the largest $2.3M.

AI Auto Pilots
Is DNTH in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Net income
−$202.1M
EPS (diluted)
−$4.08
Valuation
Market cap
$4.9B
56.3M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$55.7M
At Sep 30
Shareholder equity
$1.2B
Shares outstanding
56.3M
At Nov 2
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2023: $2.8M$2.8MFY2023FY2024: $6.2M$6.2MFY2024FY2025: $2.0M$2.0MFY2025

From DNTH's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 4). Last 12 months adds up the four latest quarters.

Next report
—
No date on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
Strong Buy
Based on 3 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
3firms
3 Buy0 Hold0 Sell
Each firm's latest rating on DNTH in the past 90 days
Average 12-month target
$134.67
▲ 54.8% upside

Based on 3 analysts who set a price target on DNTH in the past 90 days. The average target is $134.67, with a high of $156.00 and a low of $113.00, compared with the last close of $86.98.

Low $113.00Avg $134.67High $156.00
Blue marker: last close $86.98
Highest target$156.00
Average target$134.67
Lowest target$113.00
Latest rating changes
Roth CapitalInitiated
Oct 27Buy$113
JP MorganInitiated
Sep 11Buy$135
CitigroupInitiated
Sep 4Buy$156
Truist SecuritiesMaintained
Aug 6Buy$128
HC Wainwright & Co.Maintained
Aug 6Buy$158
DateFirmActionRatingPrice target
Oct 27Roth CapitalInitiatedBuy$113
Sep 11JP MorganInitiatedBuy$135
Sep 4CitigroupInitiatedBuy$156
Aug 6Truist SecuritiesMaintainedBuy$128
Aug 6HC Wainwright & Co.MaintainedBuy$158
Loading…

Technical Analysis

DNTH · as of the Nov 17 close · updated after every close
Uptrend

The stock sits between its 20 and 50 day averages. It is sitting right on its 200 day average, a level many traders watch. Momentum is improving (RSI 52). The nearest support is the swing low (May 26) at $85.43, and the nearest resistance the 200 day average at $87.27.

Short trendBullish
Long trendBullish
MomentumImproving
StretchNormal
VolatilityNormal, 5.2%/day
Key levels
$117.8852 week high+35.5%
$96.58100 day average+11.0%
$91.19Swing high (May 20)+4.8%
$89.22Pivot R1+2.6%
$87.6450 day average+0.8%
$87.36Pivot+0.4%
$87.27200 day average+0.3%
$86.98Last close
$85.43Swing low (May 26)−1.8%
$85.12Pivot S1−2.1%
$84.4220 day average−2.9%
$35.8452 week low−58.8%
Indicators
RSI (14)51.56Middle of its rangeNeutral
MACD1.27Above its signal lineBullish
Stochastic72.5Middle of its rangeNeutral
ADX (14)23.7Weak trend
Williams %R-50.7Oversold below −80, overbought above −20Neutral
CCI (20)56.8Oversold below −100, overbought above 100Neutral
Rate of change+5.2%Change over 10 sessionsBullish
ATR (14)$4.54Typical daily range, 5.2% of price
MA 10Below
MA 20Above
MA 50Below
MA 100Below
MA 200Below
What happened before, for DNTH

What happened before

See how DNTH did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow DNTH usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How DNTH has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2018.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Total alerts
1
Bullish
0
0%
Bearish
1
100%
Date span
Oct 20 – Oct 20
Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
3
Notional
$5.1M
Largest print
$2.3M
Loading…

DNTH Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲151 buying vs 122 selling
  • ▲Held by funds +2.5 pts
  • ▲Funds holding +5
  • ▲Superinvestors: 2 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding275270+1.9%
In funds' top 10810−20.0%
Held by funds119.8%117.3%+2.5 pts
New / increased43 / 10859 / 115−13.2%
Reduced / sold out84 / 3869 / 33+19.6%
Put/call ratio0.010.74−98.7%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See DNTH institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether DNTH is in one of them and how their past DNTH trades turned out.

DNTH in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered DNTH in an article yet. Here's the latest on the wider market.

About Dianthus Therapeutics

Dianthus Therapeutics is a biotechnology company based in New York that develops experimental drugs for people with severe autoimmune diseases. Its lead candidate, claseprubart, is an antibody that blocks the active form of the C1s protein, and it is designed to be injected under the skin at home. Its second candidate, DNTH212, is a fusion protein that targets two immune pathways involved in autoimmune disease. Both candidates are still in clinical trials and are not yet approved for sale.

Headquarters
New York, NY